Lead Sponsor

Eli Lilly and Company

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Participants must be females of post-menopausal status with HR+, HER2- breast cancer that has spread to internal organs
•Participants must have had at least one endocrine therapy
•Participants must be willing to use a device to answer daily questions about how they are doing for the duration of their participation in the study
•If participant has diarrhea from a previous treatment, they should talk to their doctor to ensure they have recovered enough to participate in this study

•Participants must not have breast cancer that has spread to the brain if untreated and with symptoms
•Participants must not have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy
•Participants must not have certain active infections including HIV or hepatitis
•Participants must not be pregnant or breastfeeding
•Participants must not have certain types of cancers or certain previous cancer treatments
•Participants must not have certain serious medical conditions, including heart or lung disease, or have had certain types of tissue or organ transplants

Related studies

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer

NCT06428396 · Metastatic Breast Cancer

NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer

NCT07085767 · Breast Cancer, Locally Advanced Breast Cancer, and more

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer